Table 3

Prognostic value of several parameters on FFS and OS (univariate)

Prognostic parameterImpact on FFS, %P*PImpact on OS, %P*P
Time since upfront treatment: less than 6 mo, 6 to 12 mo, more than 12 mo 17, 32, 47 <.001 <.001 23, 50, 70 <.001 <.001 
sAAIPI: low, intermediate, high 46, 35, 23 <.001 .04 81, 60, 39 <.001 <.001 
Age: under 50, 51 to 60, over 60 y 29, 28, 12 .04 .001 65, 52, 47 .02 .04 
B-symptoms: no, yes 40, 28 .04 .17 61, 39 .001 .02 
WHO performance: 0, 1 to 2 46, 20 <.001 .03 66, 38 <.001 .17 
LDH: normal, above upper limit 45, 29 .004 .15 69, 44 <.001 .<001 
Prognostic parameterImpact on FFS, %P*PImpact on OS, %P*P
Time since upfront treatment: less than 6 mo, 6 to 12 mo, more than 12 mo 17, 32, 47 <.001 <.001 23, 50, 70 <.001 <.001 
sAAIPI: low, intermediate, high 46, 35, 23 <.001 .04 81, 60, 39 <.001 <.001 
Age: under 50, 51 to 60, over 60 y 29, 28, 12 .04 .001 65, 52, 47 .02 .04 
B-symptoms: no, yes 40, 28 .04 .17 61, 39 .001 .02 
WHO performance: 0, 1 to 2 46, 20 <.001 .03 66, 38 <.001 .17 
LDH: normal, above upper limit 45, 29 .004 .15 69, 44 <.001 .<001 

FFS24 and OS24 were at a follow-up of 24 months. P values were based on likehood ratio test in Cox regression analysis. Time since upfront treatment was adjusted for WHO performance, age, and sAAIPI. sAAIPI was adjusted for WHO performance, age, and time since upfront treatment. Age was adjusted for WHO performance, sAAIPI, and time since upfront treatment. B-symptoms were adjusted for WHO performance, age, sAAIPI, and time since upfront treatment. WHO performance was adjusted for age, sAAIPI, and time since upfront treatment. LDH adjusted for WHO performance, age, and time since upfront treatment and sAAIPI.

*

P values stratified by arm, unadjusted for other factors.

P values stratified by arm, adjusted for other factors.

Close Modal

or Create an Account

Close Modal
Close Modal